-- Ionis Pharmaceuticals (IONS) 表示，一項研究表明，其 50 毫克劑量的 zilganersen 對患有亞歷山大病（一種罕見且通常致命的神經退化性疾病）的 5 歲及以上患者取得了具有統計學意義的顯著療效。 該公司週二在一份聲明中表示，這項關鍵性研究達到了其主要終點，該藥物在 10 公尺步行測試中顯示出具有臨床意義的步速穩定作用。 該公司表示，來自 Gross Motor Function Measure-88 的新數據顯示，接受 zilganersen 治療的 2 至 4 歲兒童的粗大運動功能改善程度高於研究的對照組。 Ionis 表示，zilganersen 展現出良好的安全性和耐受性，大多數不良事件的嚴重程度為輕度或中度。 Ionis 表示，該藥物正在接受美國食品藥物管理局 (FDA) 的優先審查，預計 FDA 將於 9 月 22 日前做出批准決定。
Price: $75.13, Change: $+0.25, Percent Change: +0.34%
Ginlong Technologies' (SHE:300763) net profit attributable to shareholders in 2025 jumped 7.5% year on year to 743.2 million yuan from 691.2 million yuan, according to a Shenzhen bourse filing on Monday.Earnings per share edged up to 1.88 yuan from 1.75 yuan.The Chinese PV string inverter company's revenue rose 6.3% to 6.95 billion yuan from 6.54 billion yuan a year earlier.Shares of Ginlong plunged 16% in late-afternoon trade on Monday.
CTOS Digital (KLSE:CTOS) will seek shareholders' approval to renew authority to repurchase up to 10% of the issued shares of the company, according to a Friday Malaysian bourse disclosure.Shares gained over 2% in Monday's midday trade.The holding company of credit rating agencies in Malaysia will table a resolution to renew the share buyback authority in the company's upcoming annual general meeting,CTOS will release a statement containing details of the repurchase plan with shareholders in due time, it noted.
Adani Green Energy (NSE:ADANIGREEN, BOM:541450) consolidated attributable net profit jumped to 5.14 billion Indian rupees in the fiscal fourth quarter from 3.83 billion rupees a year ago, according to a Friday filing by the renewable energy company.Earnings per share for the quarter ended March 31 climbed to 2.33 rupees from 1.26 rupees a year earlier.Power supply revenue increased year on year to 30.9 billion rupees from 26.7 billion rupees while sale of goods fell to 2.34 billion rupees from 3.85 billion rupees.Shares of the company rose nearly 1% in Monday's trade.